953 results match your criteria Respiratory Papillomatosis Recurrent


Outcomes After Human Papillomavirus Vaccination in Patients With Recurrent Respiratory Papillomatosis: A Nonrandomized Clinical Trial.

JAMA Otolaryngol Head Neck Surg 2022 Jun 2. Epub 2022 Jun 2.

Department of Genetics and Microbiology, Faculty of Science, BIOCEV, Charles University, Prague, Czech Republic.

Importance: Recurrent respiratory papillomatosis (RRP) is a rare benign chronic disease of the larynx etiologically linked with the infection of low-risk human papillomavirus (HPV). Combination of surgical and immunomodulatory therapy has limited success. Possible use of prophylactic HPV vaccine that includes HPV-6 and HPV-11 antigens has been studied. Read More

View Article and Full-Text PDF

Impaired HPV-specific T-cell response in juvenile-onset recurrent respiratory papillomatosis patients.

Clin Immunol 2022 May 27;241:109046. Epub 2022 May 27.

Laboratory of Tumor Immunology, Beijing Pediatric Research Institute, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China; Department of Otolaryngology, Head and Neck Surgery, Beijing Children's Hospital, Capital Medical University, Beijing, China; Beijing Key Laboratory for Pediatric Diseases of Otolaryngology, Head and Neck Surgery, Beijing Pediatric Research Institute, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China. Electronic address:

Immunologic dysfunction is one of the most important mechanisms underlying the initiation and development of JORRP. The study aimed to explore whether HPV-specific T-cell response was impaired in JORRP patients. We found JORRP patients had a Th2-biased cytokine profile correlated with disease severity in peripheral system. Read More

View Article and Full-Text PDF

Expanded Basal Compartment and Disrupted Barrier in Vocal Fold Epithelium Infected with Mouse Papillomavirus MmuPV1.

Viruses 2022 05 16;14(5). Epub 2022 May 16.

Department of Surgery, University of Wisconsin-Madison, Madison, WI 53705, USA.

Laryngeal infection with low-risk human papillomaviruses can cause recurrent respiratory papillomatosis (RRP), a disease with severe effects on vocal fold epithelium resulting in impaired voice function and communication. RRP research has been stymied by limited preclinical models. We recently reported a murine model of laryngeal MmuPV1 infection and disease in immunodeficient mice. Read More

View Article and Full-Text PDF

A Novel In Vivo Model of Laryngeal Papillomavirus-Associated Disease Using Papillomavirus.

Viruses 2022 05 8;14(5). Epub 2022 May 8.

Department of Surgery, University of Wisconsin-Madison, Madison, WI 53705, USA.

Recurrent respiratory papillomatosis (RRP), caused by laryngeal infection with low-risk human papillomaviruses, has devastating effects on vocal communication and quality of life. Factors in RRP onset, other than viral presence in the airway, are poorly understood. RRP research has been stalled by limited preclinical models. Read More

View Article and Full-Text PDF

A Case of Recurrent Respiratory Papillomatosis With Lung Involvement and Malignant Transformation.

Cureus 2022 Apr 22;14(4):e24370. Epub 2022 Apr 22.

Pulmonary Medicine, MD Anderson Cancer Center, Houston, USA.

Recurrent respiratory papillomatosis is a rare and complex progression of the disease due to the human papillomavirus (HPV). In this case report, we present the findings of a 53-year-old male who was diagnosed with obstructing respiratory papillomatosis of the trachea and underwent several procedures until the disease progressed to squamous cell carcinoma. Our objective with this case report is to contribute to a broader understanding of this disease by reporting a clinical case. Read More

View Article and Full-Text PDF

Evone Flow controlled ventilation: a new device for laryngotracheal surgery.

Acta Otorhinolaryngol Ital 2022 Apr;42(2):189-193

Unit of Otorhinolaryngology, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.

View Article and Full-Text PDF

The predominant site of pharyngeal lesions in patients with recurrent respiratory papillomatosis.

Eur Arch Otorhinolaryngol 2022 May 3. Epub 2022 May 3.

Department of Otorhinolaryngology, Head and Neck Surgery, Nihon University School of Medicine, 1-6 Kandasurugadai, Chiyoda, Tokyo, 1018309, Japan.

Purpose: Recurrent respiratory papillomatosis (RRP) is a disorder characterized by the frequent recurrence of benign neoplasms in the respiratory tract. Some patients with RRP develop laryngeal papilloma, while others present with extralaryngeal lesions in the nose, pharynx, and trachea. The present study aimed to determine the pharyngeal sites where RRP-related lesions develop more frequently. Read More

View Article and Full-Text PDF

Bevacizumab as treatment option for recurrent respiratory papillomatosis: a systematic review.

Eur Arch Otorhinolaryngol 2022 Apr 24. Epub 2022 Apr 24.

Department of Otorhinolaryngology-Head and Neck Surgery, Amsterdam University Medical Center, Location VUmc, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.

Purpose: To this day, there is no cure for recurrent respiratory papillomatosis (RRP). Multiple surgical procedures are performed to achieve symptom relief and prevention of airway obstruction. A promising drug for RRP is the vascular endothelial growth factor (VEGF) binding antibody bevacizumab. Read More

View Article and Full-Text PDF

High recurrence rate in patients with juvenile-onset respiratory papillomatosis and its risk factors.

Eur Arch Otorhinolaryngol 2022 Apr 20. Epub 2022 Apr 20.

Department of Otorhinolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China.

Purpose: To identify the recurrence rate and risk factors for recurrence in patients with juvenile-onset recurrent respiratory papillomatosis (JORRP).

Methods: A retrospective review was performed for all JORRP patients who underwent surgery between 2002 and 2019 at our institution. The demographic characteristics and clinical parameters were recorded. Read More

View Article and Full-Text PDF

Efficacy of cidofovir versus bevacizumab in recurrent respiratory papillomatosis: A randomized, double-blind, placebo-controlled pilot study.

Acta Otorrinolaringol Esp (Engl Ed) 2022 Mar-Apr;73(2):82-88

Práctica Médica Grupal en Otorrinolaringología, Centro Médico ABC, Campus Santa Fe. Avenida Carlos Graef Fernández 154, Colonia Tlaxala, Cuajimalpa 05330, Ciudad de México, Mexico.

Objectives: After surgical resection of papilloma, adjuvant therapy may be recommended for the control of recurrent respiratory papillomatosis (RRP). As the efficacy of adjuvant therapy remains unproven, the aim of this study was to compare the efficacy of cidofovir versus bevacizumab used as adjuvant therapies for the control of RRP.

Methods: This randomized, double-blind, placebo-controlled pilot study was performed in a national respiratory disease referral centre. Read More

View Article and Full-Text PDF

The Narrow Band Imaging as an essential complement to White Light Endoscopy in Recurrent Respiratory Papillomatosis diagnostics and follow-up process.

Otolaryngol Pol 2021 Oct;76(1):1-5

Department of Otolaryngology, Head and Neck Surgery, Poznan University of Medical Sciences, Poland.

The aim of the study is to discuss the role of NBI imaging in upper respiratory papillomatosis (RRP). In the available literature on the subject, as of 2009, there have been 117 publications on NBI imaging focusing on the diagnosis of the upper respiratory and digestive tract, especially the larynx. They discuss the following diagnostic and therapeutic problems: identifying an abnormal vascular pattern within the mucosa, differentiating benign and malignant lesions, assessing the nature of lesions under the leukoplakia plaque, pre-operative definition of laryngeal cancer margins, supporting laser procedures to obtain safe margins, postoperative monitoring after cancer treatment, detecting second simultaneous and metachronic neoplasms and primary tumors in the case of metastases from an unknown primary site. Read More

View Article and Full-Text PDF
October 2021

Reduced NK Cell Cytotoxicity by Papillomatosis-Derived TGF-β Contributing to Low-Risk HPV Persistence in JORRP Patients.

Front Immunol 2022 8;13:849493. Epub 2022 Mar 8.

Clinical Biobank, Department of Medical Research Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

The role of natural killer (NK) cells in juvenile-onset recurrent respiratory papillomatosis (JORRP) patients remains elusive. In this study, we find increased NK cell percentage, particularly CD11b-CD27- (DN) subsets in peripheral blood of JORRP patients and associated with disease activity. RNA sequencing shows a downregulated "natural killer cell-mediated cytotoxicity" feature in JORRP tumors. Read More

View Article and Full-Text PDF

Laryngeal papilloma-induced chronic airway obstruction: A case report.

Respir Med Case Rep 2022 18;36:101607. Epub 2022 Feb 18.

Department of Respiratory Medicine, Japan.

Laryngeal papilloma is a benign tumor characterized by minimal symptoms; however, in rare cases, it can cause airway obstruction and should be treated with caution. A 65-year-old woman presented to the clinic with a history of dyspnea for the past 20 years. Chest computed tomography revealed the presence of a tracheal diverticulum with an internal septum on the right side of the trachea at the apex of the lung. Read More

View Article and Full-Text PDF
February 2022

Prevalence of Epstein-Barr virus infection in recurrent respiratory papillomatosis and the influence on disease severity.

Diagn Microbiol Infect Dis 2022 May 3;103(1):115655. Epub 2022 Feb 3.

Circulating Biomarkers Laboratory, Pathology Department, Faculty of Medical Sciences, Rio de Janeiro State University, Rio de Janeiro, Brazil.

Recurrent respiratory papillomatosis (RRP) is characterized by benign papillomatous lesions in the upper airway associated with human papillomavirus infection. It has been proposed that viral coinfections may contribute to an aggressive clinical course of the disease. For this purpose, we investigated the prevalence of Epstein-Barr virus (EBV) infection among 40 RRP patients by polymerase chain reaction assay. Read More

View Article and Full-Text PDF

HPV Vaccination after Primary Treatment of HPV-Related Disease across Different Organ Sites: A Multidisciplinary Comprehensive Review and Meta-Analysis.

Vaccines (Basel) 2022 Feb 4;10(2). Epub 2022 Feb 4.

Department of Maternal and Child Health and Urological Sciences, Sapienza University of Rome, Policlinico Umberto I, 00161 Rome, Italy.

Objective: To assess evidence on the efficacy of adjuvant human papillomavirus (HPV) vaccination in patients treated for HPV-related disease across different susceptible organ sites.

Methods: A systematic review was conducted to identify studies addressing the efficacy of adjuvant HPV vaccination on reducing the risk of recurrence of HPV-related preinvasive diseases. Results were reported as mean differences or pooled odds ratios (OR) with 95% confidence intervals (95% CI). Read More

View Article and Full-Text PDF
February 2022

Comparison of Treatment for Recurrent Respiratory Papillomatosis at a Public County Versus Private Academic Hospital.

J Voice 2022 Feb 20. Epub 2022 Feb 20.

Department of Otolaryngology-Head and Neck Surgery, University of Southern California, Los Angeles, California. Electronic address:

Objective: To compare patient, disease and treatment characteristics of patients treated for recurrent respiratory papillomatosis (RRP) at a public county versus a private hospital.

Methods: A retrospective cohort study was conducted of adult patients undergoing treatment for RRP at a tertiary-care academic center (TAC, n = 48) versus public safety net hospital (PSNH, n = 14), both staffed by the same Otolaryngology providers.

Results: There was no difference between cohorts in age, gender, medical comorbidities, history of juvenile-onset presentation, or history of prior treatment at a different institution. Read More

View Article and Full-Text PDF
February 2022

Sarcoma in a Patient with Laryngeal Papillomatosis: A Case Report.

Iran J Otorhinolaryngol 2022 Jan;34(120):59-62

Department of Head and Neck Surgery, Aristotle University of Thessaloniki, Papageorgiou Hospital, Thessaloniki, Greece.

Introduction: Recurrent respiratory papillomatosis (RRP) is classically described as a benign neoplasm of the larynx. Nevertheless, transformation to dysplasia and invasive carcinoma can occur. Sarcoma of the larynx is rare. Read More

View Article and Full-Text PDF
January 2022

[Clinical features of 19 cases of lower respiratory papillomatosis].

Zhonghua Jie He He Hu Xi Za Zhi 2022 Feb;45(2):177-182

Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530021, China.

To explore the clinical characteristics and prognosis of lower respiratory papilloma(LRP)and therefore to improve clinical diagnosis and treatment. We performed a retrospective analysis of patients who were diagnosed with LRP in our department from October 2008 to October 2020. Nineteen patients were enrolled and 12 were male and 7 were female. Read More

View Article and Full-Text PDF
February 2022

Prospective, Multi-Center Study of the Anatomic Distribution of Recurrent Respiratory Papillomatosis.

Laryngoscope 2022 Feb 7. Epub 2022 Feb 7.

Department of Otolaryngology-Head and Neck Surgery, New York University Grossman School of Medicine, New York, New York, U.S.A.

Objectives/hypothesis: To create a model of the anatomic distribution, recurrence, and growth patterns of recurrent respiratory papillomatosis (RRP).

Study Design: Prospective, multi-institutional cohort study.

Methods: Adult patients with a diagnosis of RRP evaluated between August 1, 2018 and February 1, 2021 at six participating centers were invited to enroll. Read More

View Article and Full-Text PDF
February 2022

Surgery and Adjuvant Therapy Improve Derkay Scores in Adult and Pediatric Respiratory Papillomatosis.

Laryngoscope 2022 Feb 4. Epub 2022 Feb 4.

Department of Otolaryngology-Head and Neck Surgery, University of Cincinnati Medical Center, Cincinnati, Ohio, U.S.A.

Objectives/hypothesis: Comparing Derkay anatomical score at time of procedure, disease characteristics, and mean treatment interval among adult and pediatric patients with recurrent respiratory papillomatosis (RRP).

Study Design: Restrospective study.

Methods: Retrospective review of juvenile-onset (JO) and adult-onset (AO) RRP patients treated longitudinally at pediatric and adult institutions from 1999 to 2019. Read More

View Article and Full-Text PDF
February 2022

A review of the risk factors associated with juvenile-onset recurrent respiratory papillomatosis: genetic, immune and clinical aspects.

World J Pediatr 2022 02 24;18(2):75-82. Epub 2022 Jan 24.

Beijing Key Laboratory for Pediatric Diseases of Otolaryngology, Head and Neck Surgery, Beijing Pediatric Research Institute, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, 10045, China.

Background: Juvenile-onset recurrent respiratory papillomatosis (JoRRP) is one of the most common benign lesions of hyperplastic respiratory epithelial tissue in children and is predominantly caused by human papillomaviruses (HPVs) 6 and 11. The clinical course of the disease is variable, and some patients even develop a malignancy. The purpose of this review was to summarize the related factors affecting the disease course in patients with JoRRP. Read More

View Article and Full-Text PDF
February 2022

Systemic Bevacizumab Treatment for Recurrent Respiratory Papillomatosis: Long-Term Follow-Up.

Laryngoscope 2022 Jan 19. Epub 2022 Jan 19.

Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, U.S.A.

Objectives/hypothesis: Systemic bevacizumab is a new adjuvant therapy for recurrent respiratory papillomatosis (RRP) that has shown promising preliminary results in children. The objective of this study was to report the largest series to date that includes long-term follow-up data on bevacizumab treatment.

Study Design: Retrospective chart review. Read More

View Article and Full-Text PDF
January 2022

Role of E6 in Maintaining the Basal Cell Reservoir during Productive Papillomavirus Infection.

J Virol 2022 03 12;96(5):e0118121. Epub 2022 Jan 12.

Department of Pathology, University of Cambridgegrid.5335.0, Cambridge, United Kingdom.

Papillomaviruses exclusively infect stratified epithelial tissues and cause chronic infections. To achieve this, infected cells must remain in the epithelial basal layer alongside their uninfected neighbors for years or even decades. To examine how papillomaviruses achieve this, we used the MmuPV1 (Mus musculus papillomavirus 1) model of lesion formation and persistence. Read More

View Article and Full-Text PDF

Malignant Transformation of Juvenile Recurrent Respiratory Papillomatosis.

Gulf J Oncolog 2021 May;1(36):79-81

Department of Otorhinolaryngology-Head & Neck Surgery, School of Medical Sciences, Universiti Sains Malaysia, Health Campus 16150 Kota Bharu, Kelantan, Malaysia.

Malignant transformation of recurrent respiratory papillomatosis (RRP) is a rare entity occurring in only less than 5% of patients with RRP. The risk of transformation can arise even in the absence of risk factors such as smoking and radiation. We describe a patient with juvenile RRP diagnosed since childhood, who suffered malignant transformation into a squamous cell carcinoma after 29 years. Read More

View Article and Full-Text PDF

Comprehensive multiomic characterization of human papillomavirus-driven recurrent respiratory papillomatosis reveals distinct molecular subtypes.

Commun Biol 2021 12 20;4(1):1416. Epub 2021 Dec 20.

Section on Translational Tumor Immunology, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, MD, USA.

Recurrent respiratory papillomatosis (RRP) is a debilitating neoplastic disorder of the upper aerodigestive tract caused by chronic infection with low-risk human papillomavirus types 6 or 11. Patients with severe RRP can require hundreds of lifetime surgeries to control their disease and pulmonary papillomatosis can be fatal. Here we report the comprehensive genomic and transcriptomic characterization of respiratory papillomas. Read More

View Article and Full-Text PDF
December 2021

Tracheotomy as a predictor of remission and demise for juvenile-onset recurrent respiratory papillomatosis.

Acta Otolaryngol 2022 Jan 19;142(1):84-88. Epub 2021 Dec 19.

Department of Otorhinolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China.

Backgroud: The pros and cons of tracheotomy, as a classic treatment of juvenile-onset recurrent respiratory papillomatosis (JORRP), have gradually been recognized, but the exact impact of tracheotomy on remission and demise is not clear.

Objectives: To investigate the predicting influence of tracheotomy on prognosis for JORRP.

Material And Methods: Three hundred forty two patients with JORRP treated in Beijing Tongren Hospital were retrospectively reviewed. Read More

View Article and Full-Text PDF
January 2022

Real-world impact and effectiveness assessment of the quadrivalent HPV vaccine: a systematic review of study designs and data sources.

Expert Rev Vaccines 2022 Feb 13;21(2):227-240. Epub 2021 Dec 13.

Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Stockholm, Sweden.

Introduction: Vaccine effectiveness and impact studies are typically observational, generating evidence after vaccine launch in a real-world setting. For human papillomavirus (HPV) vaccination studies, the variety of data sources and methods used is pronounced. Careful selection of study design, data capture and analytical methods can mitigate potential bias in such studies. Read More

View Article and Full-Text PDF
February 2022

HPV and Recurrent Respiratory Papillomatosis: A Brief Review.

Life (Basel) 2021 Nov 22;11(11). Epub 2021 Nov 22.

College of Medicine, QU Health, Qatar University, Doha 2713, Qatar.

Recurrent Respiratory Papillomatosis (RRP) is a rare but severe manifestation of human papillomavirus (HPV). As our knowledge about HPV infections has expanded, it has become possible to understand the course of RRP disease and unravel plausible efficient methods to manage the disease. However, the surge in reports on HPV has not been accompanied by a similar increase in research about RRP specifically. Read More

View Article and Full-Text PDF
November 2021

Genetic and methylation status of CDKN2A (p14/p16) and TP53 genes in recurrent respiratory papillomatosis.

Hum Pathol 2022 01 23;119:94-104. Epub 2021 Nov 23.

Circulating Biomarkers Laboratory, Pathology Department, Faculty of Medical Sciences, Rio de Janeiro State University, Rio de Janeiro 20550-170, Brazil.

Recurrent respiratory papillomatosis (RRP) is a rare and chronic disease affecting the upper airway with papillomatous lesions caused by the human papillomavirus (HPV) infection, especially HPV-6 and/or HPV-11 types. Little is known about the genetic and epigenetic drivers in RRP pathophysiology. For this purpose, we analyzed 27 papillomatous lesions from patients with RRP to evaluate somatic mutations and methylation status in CDKN2A (p14/p16) and TP53, which are key tumor suppressor genes for the cell cycle control. Read More

View Article and Full-Text PDF
January 2022